M. Regueiro

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
M D Regueiro, Miguel D Regueiro, M Regueiro, M. Regueiro, Miguel D. Regueiro, Miguel Regueiro
Publication record
621 papers · 21,712 citations · H-index 58

PAPERS

Mo1039 CREATION OF A SUBSPECIALTY LEARNING COMMUNITY FOR ADVANCED INFLAMMATORY BOWEL DISEASE FELLOWS ANCHORED IN COMPETENCY BASED EDUCATION: THE MILESTONE INITIATIVE
20230 citationsauthor #9
Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies.
202315 citationsauthor #3
Tu1773 POSTOPERATIVE PROPHYLAXIS WITH NEW COMPARED TO RECYCLED BIOLOGIC CLASSES HAVE SIMILAR RATES OF BUT EARLIER TIME TO POSTOPERATIVE RECURRENCE IN BIOLOGIC EXPERIENCED CROHN'S DISEASE PATIENTS UNDERGOING ILEOCOLONIC RESECTION
20230 citationsauthor #13
Postoperative Crohn's Disease.
20231 citationsauthor #2
Sa1780 IMPACT OF BARIATRIC SURGERY ON THE OUTCOMES OF INFLAMMATORY BOWEL DISEASE: A U.S. COHORT PROPENSITYMATCHED STUDY
20230 citationsauthor #7
Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn’s disease
20234 citationsauthor #10
Sa1781 THE OUTCOMES OF IBD IN PATIENTS WHO RECEIVED TOCILIZUMAB DURING COVID-19 PANDEMIC: A U.S. COHORT PROPENSITY SCORE MATCHED STUDY
20230 citationsauthor #5
Anastomotic Configuration and Temporary Diverting Ileostomy Do Not Increase Risk of Anastomotic Stricture in Postoperative Crohn's Disease
20234 citationsauthor #11
Mo1774 RISK OF EXTRA-INTESTINAL SOLID ORGAN MALIGNANCY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A US-BASED PROPENSITY MATCHED COHORT STUDY
20230 citationsauthor #6
Tu1742 ENDOSCOPIC, HISTOLOGIC, AND COMBINED OUTCOMES WITH REINITIATION OF OZANIMOD AFTER TEMPORARY DISCONTINUATION: 2-YEAR INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
20230 citationsauthor #1
201 SESSILE SERRATED POLYP DETECTION RATE IN ASYMPTOMATIC AVERAGE RISK INDIVIDUALS WITH POSITIVE FECAL IMMUNOCHEMICAL AND MULTITARGET STOOL DNA TEST: A SYSTEMATIC REVIEW AND META-ANALYSIS
20230 citationsauthor #5
Experience and measurement of fatigue in adults with Crohn’s disease: results from qualitative interviews and a longitudinal 2-week daily diary pilot study
20234 citationsauthor #1
Mo1745 HISTOLOGIC ACTIVITY DESPITE ENDOSCOPIC REMISSION PREDICTS CROHN'S DISEASE RECURRENCE FOLLOWING ILEOCOLONIC RESECTION
20232 citationsauthor #12
Su1704 CHARACTERIZATION OF CARDIAC CONDUCTION ABNORMALITIES REPORTED IN THE PHASE 3 ELEVATE PROGRAM
20230 citationsauthor #5
Preoperative Use of Multiple Advanced Therapies Is Not Associated With Endoscopic Inflammatory Pouch Diseases.
20231 citationsauthor #9
Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus.
202311 citationsauthor #15
237 DEVELOPMENT AND VALIDATION OF A RISK CALCULATOR FOR MORTALITY AMONG GENERAL SURGERY PATIENTS AT THE TIME OF INTER-HOSPITAL TRANSFER
20230 citationsauthor #5
Mo1767 USING FECAL CALPROTECTIN TO PREDICT ENDOSCOPIC RECURRENCE IN POST-OPERATIVE CROHN'S DISEASE
20230 citationsauthor #14
Sa1831 SIMILAR POSTOPERATIVE RECURRENCE RISK AMONGST INTERNAL PENETRATING CROHN'S DISEASE PHENOTYPES
20230 citationsauthor #12
Efficacy of biologic and small molecule agents as second‐line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity‐matched cohort study
202319 citationsauthor #7
963 BOWEL URGENCY OUTCOMES ARE ASSOCIATED WITH IMPROVEMENT IN FATIGUE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A POOLED ANALYSIS OF LUCENT-1 AND LUCENT-2 PHASE 3 TRIALS
20232 citationsauthor #7
Su1711 EFFICACY AND SAFETY OF TOFACITINIB AFTER FAILURE OF ANTI-TNF AGENT IN PATIENTS WITH ULCERATIVE COLITIS: A US-BASED PROPENSITY MATCHED COHORT STUDY
20230 citationsauthor #6
Su1778 LOW RATES OF PNEUMOCOCCAL VACCINATION ADMINISTRATION IN ADULT PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A MULTICENTER POPULATION-BASED STUDY
20230 citationsauthor #13
Su1121 BIOLOGIC THERAPY PREVENTS COVID RELATED COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS
20230 citationsauthor #8
Sa1779 THE EPIDEMIOLOGY AND CHARACTERISTICS OF DE NOVO IBD AFTER SOLID ORGAN OR HEMATOPOIETIC STEM CELL TRANSPLANT BETWEEN 2011-2021: A LARGE POPOULATION-BASED STUDY
20230 citationsauthor #7
Mo1563: POST-OPERATIVE IMMUNOSUPPRESSIVE THERAPY FOLLOWING ILEAL POUCH ANAL ANASTOMOSIS CREATION: AN ASSESSMENT USING THE TRINETX COHORT
20220 citationsauthor #7
Remestemcel-L allogeneic bone marrow-derived mesenchymal stem cell product to treat medically refractory Crohn's colitis: preliminary phase IB/IIA study.
20224 citationsauthor #5
S964 Impact of Biologics Therapy on the Prevalence of Erectile Dysfunction Among Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Study
20220 citationsauthor #5
S974 Comparison of Surgical Rates in Biologic Naive Crohn's Disease Patients on Ustekinumab and Vedolizumab
20220 citationsauthor #9
Mo1545: IMPACT OF BIOLOGICS THERAPY ON THE PREVALENCE OF DEMENTIA AMONG OLDER PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE POPULATION-BASED STUDY
20220 citationsauthor #7
S1494 Gastroenterology Fellowship Virtual Interviews: Applicant and Faculty Perceptions on Virtual Interview Advantages and Barriers
20220 citationsauthor #18
S971 The Prevalence of Vasculitis Is Increased in Inflammatory Bowel Disease, but Decreased After Anti-TNF Treatment: A Population-Based Study
20220 citationsauthor #4
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease.
202258 citationsauthor #29
S923 Anti-TNFs Are Associated With Lower Prevalence of Cerebrovascular Disease in Patients With Inflammatory Bowel Disease
20221 citationsauthor #5
15: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS
20220 citationsauthor #14
S96 An Exploration of the Experience and Measurement of Fatigue in Adults With Crohn’s Disease
20220 citationsauthor #1
P563 Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme
20221 citationsauthor #3
Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD
20224 citationsauthor #8
Burden of Fatigue Among Patients with Ulcerative Colitis and Crohn’s Disease: Results from a Global Survey of Patients and Gastroenterologists
202227 citationsauthor #1
Intraabdominal septic complications after ileocolic resection increases risk for endoscopic and surgical postoperative Crohn's disease recurrence.
202213 citationsauthor #12
Venous Thromboembolism in Patients Admitted for IBD: An Enterprise-Wide Experience of 86,000 Hospital Encounters
20228 citationsauthor #4
S1045 Racial Disparities in Utilization of Medications in Inflammatory Bowel Disease Patients
20221 citationsauthor #6
S872 Increased Risk of Gout in Patients With Inflammatory Bowel Disease: A Population-Based Study
20220 citationsauthor #5
Sa1605: CLINICAL CHARACTERISTICS, MEDICATION UTILIZATION, AND CLINICAL OUTCOMES OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND HEART FAILURE: A MULTICENTER NETWORK STUDY
20220 citationsauthor #11
S1042 Comparison of Colectomy Rates in Biologic Naive Ulcerative Colitis Patients on Ustekinumab and Vedolizumab
20220 citationsauthor #9
S1044 Prevalence of Vitiligo Among IBD and Celiac Disease Patients: Results From a Population-Based Study
20220 citationsauthor #7
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
202212 citationsauthor #12
Mild neoterminal ileal post‐operative recurrence of Crohn’s disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions
202224 citationsauthor #13
S969 Crohn’s Disease Patients Treated With Anti-TNFs Have Lower Rates of Interstitial Lung Disease
20220 citationsauthor #5
IBD MIMICS PRESENTED AT IBD LIVE: WHEN IT IS NOT INFLAMMATORY BOWEL DISEASE
20220 citationsauthor #31
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
202258 citationsauthor #46
The Natural Course of Pancreatic Cysts in Inflammatory Bowel Disease
20221 citationsauthor #9
Tu1472: RAPIDITY OF OZANIMOD-INDUCED SYMPTOMATIC RESPONSE AND REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE INDUCTION PERIOD OF TRUE NORTH
20220 citationsauthor #7
Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial
202213 citationsauthor #11
Rate and risk factors of postoperative endoscopic recurrence of moderate- to high-risk Crohn's disease patients - A real-world experience from a Middle Eastern cohort
20225 citationsauthor #11
S1055 Crohn’s Disease Patients Treated With Anti-TNFs Have Lower Rates of Myocarditis
20220 citationsauthor #4
S806 Impact of Biologics Therapy on the Prevalence of Pregnancy Complications Among Women With Inflammatory Bowel Disease: A Nationwide Population-Based Study
20220 citationsauthor #4
S1020 The Prevalence of Asthma Are Increased in Inflammatory Bowel Disease, but Decreased After Biologics Treatment: A Population-Based Study
20220 citationsauthor #4
Inflammatory Bowel Disease and Helicobacter pylori: Protective or Present?
202212 citationsauthor #4
Sa1604: CLINICAL CHARACTERISTICS, DISEASE-SPECIFIC OUTCOMES, AND MEDICATION UTILIZATION AMONG PATIENTS WITH ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS IN THE USA: A MULTICENTER NETWORK STUDY
20220 citationsauthor #10
S809 Impact of Biologics Therapy on the Prevalence of Parkinson’s Disease Among Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Study
20220 citationsauthor #4
401: ANASTOMOTIC CONFIGURATION AND DIVERTING OSTOMY DOES NOT INCREASE THE RISK OF POSTOPERATIVE ANASTOMOTIC STRICTURES IN CROHN'S DISEASE
20220 citationsauthor #15
S776 Rates of Melanoma and Non-Melanoma Skin Cancers Among IBD Patients Treated With Non-Anti-TNF Advanced Therapies
20220 citationsauthor #15
S933 Racial Disparities in Extraintestinal Manifestations in Patients With Inflammatory Bowel Disease
20220 citationsauthor #5
S980 Prevalence of Non-Hodgkin’s Lymphoma Among IBD and Celiac Disease Patients: Results From a Population-Based Study
20220 citationsauthor #5
456: CHRONOLOGIC AGE IS NOT ASSOCIATED WITH RISK OF POSTOPERATIVE RECURRENCE IN CROHN'S DISEASE
20220 citationsauthor #14
S31 The Impact of Early vs Late Biologic Initiation Among Real-World Patients With Crohn’s Disease in TARGET-IBD
20222 citationsauthor #3
S914 Impact of Anti-TNF on the Prevalence of Hepatobiliary and Pancreatic Disorders Associated With Inflammatory Bowel Disease: A Population-Based Study
20220 citationsauthor #5
Sa1591: INTRAABDOMINAL SEPTIC COMPLICATIONS AFTER ILEOCOLIC RESECTION INCREASES ENDOSCOPIC POSTOPERATIVE CROHN'S DISEASE RECURRENCE
20220 citationsauthor #11
Prevalence of Obstructive Sleep Apnea Is Increased in Patients With Inflammatory Bowel Disease: A Large, Multi-Network Study
202210 citationsauthor #4
S815 Patients With Neuro-Developmental Disorders Are Associated With a Higher Risk of Inflammatory Bowel Disease: A Nationwide Population-Based Study
20220 citationsauthor #5
Tu1450: EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
20222 citationsauthor #8
S122 Three-Dimensional Morphologic Analysis of Severe, Occult Ileoanal Pouch Pathology Using Manual Staple-Line Segmentation: A Proof-of-Concept Study
20220 citationsauthor #18
S1024 Dermatologic Manifestations in Patients With Inflammatory Bowel Disease
20220 citationsauthor #15
Mo1555: PRE-OPERATIVE USE OF MULTIPLE BIOLOGIC AND SMALL MOLECULE DRUGS IS NOT ASSOCIATED WITH SUBSEQUENT ENDOSCOPIC INFLAMMATORY POUCH DISEASES
20220 citationsauthor #11
719: POSTOPERATIVE CROHN'S DISEASE RECURRENCE RISK AND OPTIMAL BIOLOGIC TIMING AFTER TEMPORARY DIVERSION FOLLOWING ILEOCECAL RESECTION
20220 citationsauthor #14
Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection.
202232 citationsauthor #16
Tu1448: EFFECT OF BASELINE DISEASE CHARACTERISTICS ON CLINICAL OUTCOMES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS TREATED WITH UPADACITINIB: RESULTS FROM A PHASE 3 TRIALS PROGRAMME
20220 citationsauthor #3
Sa1603: CLINICAL CHARACTERISTICS, DISEASE-SPECIFIC OUTCOMES, AND MEDICATION UTILIZATION AMONG PATIENTS WITH CHRON'S DISEASE AND MULTIPLE SCLEROSIS IN THE USA: A MULTICENTER NETWORK STUDY
20220 citationsauthor #10
S745 Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis
20211 citationsauthor #13
Patients With Inflammatory Bowel Disease on Treatment Have Lower Rates of Celiac Disease.
20215 citationsauthor #9
Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD
20214 citationsauthor #6
Hypoalbuminemia, Not Biologic Exposure, is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection.
202135 citationsauthor #11
612 IMPACT OF BIOLOGICS ON THE PREVALENCE OF OSTEOPOROSIS AND BONE FRACTURES AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE POPULATION-BASED STUDY
20210 citationsauthor #6
S823 Demographics and Clinical Characteristics of Crohn’s Disease Patients Switched to a Non-Anti-TNF Agent After Initial Primary Non-Response With Anti-TNF Agent: A National Database Study
20210 citationsauthor #13
First or Second Biologic in Inflammatory Bowel Disease
20210 citationsauthor #5
Fr525 BIOSIMILAR SWITCH IN A LARGE QUATERNARY CARE AMERICAN MEDICAL INSTITUTION DOES NOT RESULT IN WORSENING OF INFLAMMATORY BOWEL DISEASE ACTIVITY
20211 citationsauthor #7
Ileocolic Resection for Crohn Disease: The Influence of Different Surgical Techniques on Perioperative Outcomes, Recurrence Rates, and Endoscopic Surveillance.
202124 citationsauthor #4
Su455 SIMILAR RATES OF POSTOPERATIVE OBJECTIVE RECURRENCE IN ADULT CROHN'S DISEASE PATIENTS ON DIFFERENT POSTOPERATIVE BIOLOGIC THERAPIES
20210 citationsauthor #7
S3341 When It Is Not Inflammatory Bowel Disease: IBD Mimics Presented at IBD Live
20210 citationsauthor #26
Mesenteric Excision and Exclusion for Ileocolic Crohn’s Disease: Feasibility and Safety of an Innovative, Combined Surgical Approach With Extended Mesenteric Excision and Kono-S Anastomosis
202129 citationsauthor #8
S954 Impact of Isolated Anastomotic Inflammation on Future Disease Progression: A Systematic Review and Meta-analysis
20210 citationsauthor #5
Sa552 UTILIZATION OF BIOLOGIC MEDICATIONS AND IMMUNOMODULATORS AMONG PATIENTS WITH HEART FAILURE AND ULCERATIVE COLITIS IN THE UNITED STATES BETWEEN 2015 AND 2020: A POPULATION-BASED STUDY
20210 citationsauthor #8
S955 Differential Risk of Colorectal Cancer in Inflammatory Bowel Disease Patients Treated With Advanced Therapies, Immunomodulators, and 5-Aminosalicylates: A Multi-Research Network Study Utilizing the TrinetX Database
20210 citationsauthor #11
DOP17 In high-risk Crohn’s Disease patients, anastomosis configuration types have similar rates of endoscopic recurrence
20211 citationsauthor #9
S713 Changing Biologic Mechanism After Detection of Endoscopic Postoperative Recurrence Promotes Endoscopic Remission
20210 citationsauthor #14
Inflammatory Bowel Disease Patients’ Perspectives of Clinical Trials: A Global Quantitative and Qualitative Analysis
202113 citationsauthor #7
Small Bowel Crohn’s Disease Recurrence is Common After Total Proctocolectomy for Crohn’s Colitis
20217 citationsauthor #5
Anal Squamous Cell Carcinoma in Ulcerative Colitis: Can Pouches Withstand Traditional Treatment Protocols?
20215 citationsauthor #5
Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease.
20218 citationsauthor #14

TIMELINE

1998 0 citations

1999 0 citations

2000 4 citations

2001 23 citations

2002 273 citations

2003 607 citations

2004 48 citations

2005 64 citations

2006 3,556 citations

2007 2,388 citations

2008 2,759 citations

2009 814 citations

2010 2,860 citations

2011 511 citations

2012 325 citations

2013 334 citations

2014 735 citations

2015 735 citations

2016 1,249 citations

2017 584 citations

2018 1,819 citations

2019 821 citations

2020 499 citations

2021 298 citations

2022 288 citations

2023 63 citations

Unknown 71 citations

M. Regueiro

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT